2023
An international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrials
2021
Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
de Boer N, Guloksuz S, van Baal C, Willebrands L, Deenik J, Vinkers C, Rossum I, Zinkstok J, Wilting I, Zantvoord J, Backx F, Swildens W, Schouw M, Bogers J, Hulshof F, de Knijff R, Duindam P, Veereschild M, Bak M, Frederix G, de Haan L, van Os J, Cahn W, Luykx J. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. BMC Psychiatry 2021, 21: 4. PMID: 33402159, PMCID: PMC7783702, DOI: 10.1186/s12888-020-02992-4.Peer-Reviewed Original ResearchConceptsNetherlands Trial RegisterLifestyle interventionQuality of lifeTreatment inceptionOutcome measuresWeight gainAntipsychotic-induced weight gainSafety of metforminUse of metforminCommon adverse effectsSecondary outcome measuresPrimary outcome measureWeeks of treatmentBody weight lossMulti-center trialType 2 diabetesMajor health problemYears of ageSchizophrenia spectrum disordersTrials RegisterMetabolic syndromeOptimal management strategyExercise programMetformin treatmentDietary consultation
2014
Clinical Features of Night Eating Syndrome among Depressed Patients
Kucukgoncu S, Tek C, Bestepe E, Musket C, Guloksuz S. Clinical Features of Night Eating Syndrome among Depressed Patients. European Eating Disorders Review 2014, 22: 102-108. PMID: 24436087, DOI: 10.1002/erv.2280.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxiety DisordersBody Mass IndexCircadian RhythmDepressionFeeding and Eating DisordersFeeding BehaviorFemaleHumansInterviews as TopicMaleMiddle AgedObesityPersonality InventoryPrevalencePsychiatric Status Rating ScalesQuality of LifeRegression AnalysisSocioeconomic FactorsStress, PsychologicalSurveys and QuestionnairesSyndromeYoung AdultConceptsPittsburgh Sleep Quality IndexBeck Depression InventoryBeck Anxiety InventoryClinical featuresDepressed patientsDepression InventoryNon-NE patientsNight eating syndromeSleep Quality IndexSample of patientsAnxiety InventorySeverity of anxietyNight Eating QuestionnaireSocio-demographic formSmoking statusDaytime dysfunctionSleep qualityDepressed outpatientsPatientsSyndromeEating QuestionnaireStudy sampleBMISignificant differencesDepression
2013
Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability
Guloksuz S, Wichers M, Kenis G, Russel M, Wauters A, Verkerk R, Arts B, van Os J. Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability. PLOS ONE 2013, 8: e60435. PMID: 23544139, PMCID: PMC3609785, DOI: 10.1371/journal.pone.0060435.Peer-Reviewed Original ResearchConceptsCrohn's diseaseDisease activityImmune activationDepressive symptomsDepression scoresTrp availabilityΑ treatmentTryptophan availabilityNegative APPsAnti-tumor necrosis factorPast depressive disorderTNF-α treatmentSymptoms of depressionQuality of lifeCD patientsIBDQ scoreImmune markersComorbid depressionDepressive disorderNecrosis factorInflammatory reactionPatientsSymptomsDiseaseTreatment